Senior Staff Software Engineer, Backend (Discovery / Search)
AffirmFull Time
Senior (5 to 8 years)
Candidates should possess a minimum of 8 years of related experience with a bachelor's degree, or a PhD with 3 years of experience for Software Engineer II, and a minimum of 10 years of related experience with a bachelor's degree or a PhD with 5 years of experience for Senior Software Engineer. A PhD in Chemistry or Biology or a related field, or similar experience is preferred. Strong software and technical skills are required, including proficiency in Python and its scientific computing ecosystem (e.g., Pydantic, asyncio, FastAPI), experience with Kubernetes (e.g., ability to create/manage Helm charts), a track record of designing and developing in coordination with frontend developers, the ability to work with DevOps/CloudOps engineers, and communication skills with ML engineers.
The Software Engineer will contribute to the development, testing, and release of the backend server for the Drug Discovery platform, working within a cross-functional team that spans the full domain of drug discovery. Responsibilities include supporting a software platform for the Drug Discovery Design-Make-Test-Analyze (DMTA) process, developing efficient and maintainable backend server software with Postgres integration, deploying to Kubernetes in AWS in collaboration with cloud engineers, and collaborating on the creation, testing, and maintenance of the platform. The role also involves contributing to continuous improvement in software best practices, including architecture development, design, testing, release management, and documentation, participating in code reviews, and collaborating with ML scientists, Computation Chemists, Chemists, and Biologists to understand platform requirements. Clear oral communication of work in meetings and company demos is also expected.
Develops therapies for CNS disorders
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.